Cedar Crosse Research Center | Chicago, IL
Status and phase
Conditions
Treatments
About
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Full description
This is a Phase 1/ 2 study that will examine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple dose levels of BMF-219, an orally bioavailable selective covalent inhibitor of menin, in healthy subjects and in subjects with T2D. This study will assess the effect of BMF-219 as single ascending dose (SAD) and multiple ascending dose (MAD).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Healthy Subject Inclusion Criteria:
Subjects with T2D: (MAD Cohorts) Inclusion Criteria:
Subjects with T2D: (Expansion Cohort) Inclusion Criteria:
Exclusion criteria
Healthy Subject Exclusion Criteria:
Subjects with T2D (MAD Cohorts) Exclusion Criteria:
Subjects with T2D (Expansion Cohort) Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
414 participants in 5 patient groups
Loading...
Central trial contact
Rima Sakhapara; Sanchita Mourya, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal